scholarly journals Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Bo Fu ◽  
Peng Yan ◽  
Shan Zhang ◽  
Yan Lu ◽  
Li Pan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Efficacy ◽  
Early Stage ◽  
Histological Grade ◽  
Diagnostic Value ◽  
Noninvasive Diagnosis ◽  
High Positive Rate ◽  
Positive Rate ◽  
One Year ◽  
Gastric Cancer Patients

Identification of early-stage tumor and monitoring therapeutic efficacy and recurrence or metastasis of colorectal cancer (CRC) are urgently warranted for improving the outcome of CRC patients and reducing the disease-related mortality. In this study, we evaluated the diagnostic value of cell-free circulating methylated SEPT9 (mSEPT9) for CRC and beyond CRC and examined the potentiality of mSEPT9 in assessing therapeutic efficacy and monitoring recurrence of CRC. Our results confirmed the favorable diagnostic value of plasma mSEPT9 for CRC, with a sensitivity of 61.22% (95% confidence interval (CI): 51.33%–70.27%) and specificity of 93.7% (95% CI: 91.09%–95.57%) using 2/3 algorithm. The positive rate of mSEPT9 in CRC was correlated with tumor size, histological grade, and general histological type (P<0.05). Beyond CRC, gastric cancer patients also presented a high positive rate of plasma mSEPT9 (70%). The conversions between preoperative and postoperative plasma mSEPT9 reflected the therapeutic efficacy of curatively intended surgery for CRC patients. The persistent positivity of plasma mSEPT9 after surgery (within 7–14 days) was highly associated with impending recurrences or metastases (within one year), with a sensitivity of 100%. Postoperative mSEPT9 status during follow-up also provided valuable indication for CRC recurrence or metastases, with a good consistency (kappa = 0.818, P=0.001). Our results verified the reliability of plasma mSEPT9 as a biomarker for noninvasive diagnosis of CRC. More significantly, we revealed its valuable role in appraising CRC therapeutic efficacy and monitoring CRC recurrences or metastases. Further studies with larger sample sizes are needed to verify and elucidate the clinical utility of the promising findings.

scholarly journals The Diagnostic Value of Serum L1CAM in Patients With Colorectal Cancer

2020 ◽  
Vol 19 ◽  
pp. 153303382092097
Author(s):  
Ling-Yu Chu ◽  
Dong-Ming Guo ◽  
Jun-Tian Chen ◽  
Wang-Kai Fang ◽  
Jian-Jun Xie ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cell Adhesion ◽  
Confidence Interval ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Operating Characteristic ◽  
Early Stage ◽  
Diagnostic Value ◽  
L1 Cell Adhesion Molecule ◽  
Normal Controls

Objective: Colorectal cancer is one of the most important malignant cancer in the world with high incidence and mortality. Some studies have found that the expression of low serum L1 cell adhesion molecule is associated with poor prognosis in some malignancies. It is suggested that L1 cell adhesion molecule is a candidate serum marker for certain tumors. However, the relationship between serum L1 cell adhesion molecule and colorectal cancer, especially about the diagnostic value, is rarely reported. Therefore, this study aimed to evaluate the diagnostic potential of serum L1 cell adhesion molecule in patients with colorectal cancer. Methods: Enzyme-linked immunosorbent assay was carried out to detect L1 cell adhesion molecule level in sera of 229 patients with colorectal cancer and 145 normal controls. Receiver operating characteristic curves were employed to calculate the accuracy of diagnosis. Results: The levels of serum L1 cell adhesion molecule in the colorectal cancer group were significantly lower than that in normal controls ( P < .05). In the normal group, the area under the receiver operating characteristic curve (area under the curve) of all colorectal cancer was 0.781 (95% confidence interval: 0.734-0.828) and early-stage colorectal cancer was 0.764 (95% confidence interval: 0.705-0.823). With optimized cutoff of 17.760 ng/mL, L1 cell adhesion molecule showed certain diagnostic value with specificity of 90.3% and sensitivities of 43.2% and 36.2% in colorectal cancer and early-stage colorectal cancer, respectively. Clinical data analysis showed that the levels of L1 cell adhesion molecule were significantly correlated with gender ( P < .05) and early and late stages ( P < .05). Furthermore, when compared with carcinoembryonic antigen, serum L1 cell adhesion molecule had significantly improved diagnostic accuracy for both colorectal cancer and early-stage colorectal cancer. Conclusions: Our study demonstrated that serum L1 cell adhesion molecule might be served as a potential biomarker for the diagnosis of colorectal cancer.

scholarly journals Association and diagnostic value of serum SPINK4 in colorectal cancer

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e6679 ◽  
Author(s):  
Mingzhi Xie ◽  
Kezhi Li ◽  
Jilin Li ◽  
Dongcheng Lu ◽  
Bangli Hu
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Cancer Patients ◽  
Characteristic Curve ◽  
Disease Free Survival ◽  
Diagnostic Value ◽  
Healthy Controls ◽  
Significant Difference ◽  
Peptidase Inhibitor ◽  
Gastric Cancer Patients

The role of serum serine peptidase inhibitor, Kazal type 4 (SPINK4), in colorectal cancer (CRC) is largely unknown. This study aimed to explore the association and diagnostic value of serum SPINK4 in CRC. A total of 70 preoperative CRC patients, 30 postoperative CRC patients, 30 gastric cancer patients, and 30 healthy controls were enrolled. Using enzyme-linked immunosorbent assays, we found that the serum SPINK4 level was significantly increased in preoperative CRC compared with postoperative CRC patients, gastric cancer patients, and healthy controls (p < 0.05). The serum SPINK4 level was remarkably elevated in colon cancer compared with rectal cancer and was enhanced in the M1 stage compared with the M0 stage (p < 0.05). The area under the receiver operating characteristic curve of serum SPINK4 level in the diagnosis of CRC was 0.9186, with a sensitivity and specificity of 0.886 and 0.900, respectively, and a cut-off value of 2.065. There was no significant difference between high and low expression of serum SPINK4 regarding the overall survival time and disease-free survival (p > 0.05). This study demonstrated that the serum SPINK4 level increased in CRC and was associated with the location and distant metastasis of CRC. It had a high diagnostic value in CRC but was not associated with the survival of CRC patients.

WITH SURGICAL REMOVAL OR ADJUVANT CHEMOTHERAPY INCREASE THE TWO-YEAR SURVIVAL AND ASSOCIATED CLINICOPATHOLOGIC FACTORS IN CATS WITH MAMMARY CARCINOMAS

2019 ◽  
Vol 45 (03) ◽  
pp. 57-66
Author(s):  
Ti-Yun Lo ◽  
Yu-Ching Feng ◽  
Yi-Ping Yang ◽  
Jiunn-Wang Liao ◽  
Shih-Chieh Chang
Keyword(s):  
Adjuvant Chemotherapy ◽  
Early Stage ◽  
Histological Grade ◽  
Biological Behavior ◽  
Prognostic Indicators ◽  
Surgical Removal ◽  
Mammary Carcinomas ◽  
Clinicopathologic Factors ◽  
Advanced Stages ◽  
One Year

Due to the aggressive biological behavior, a large number of studies attempt to identify the prognostic indicators for feline mammary carcinoma (FMC). In this study, we retrospectively identified the prognostic indicators and evaluated the effect of surgery with or without adjuvant chemotherapy on 47 cats with FMCs. Over a two-year follow-up period, surgical removal was significantly associated with greater overall survival time (OST). In cats that underwent surgical treatment, median OST was longer in cats that underwent surgery with adjuvant chemotherapy (540 days) than cats that underwent surgery without chemotherapy (398 days). In addition, cats with FMCs in early stage (I or II) had longer OST than cats in advanced stages. Further, through multivariate analyses, the histological grade was found to be significantly associated with a survival of two years. Cats with FMCs at high grade were most likely to have a mean or median OST of less than one year. In summary, stage, grade and the size of tumor were all prognostic factors, in which histological grade was found to be the only significant factor in cats with mammary carcinomas through multivariate analysis.

scholarly journals Serum SARS-COV-2 Nucleocapsid Protein: A Sensitivity and Specificity Early Diagnostic Marker for SARS-COV-2 Infection

2020 ◽  
Author(s):  
Tao Li ◽  
Li Wang ◽  
Huihui Wang ◽  
Xuemei Li ◽  
Shubing Zhang ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Sensitivity And Specificity ◽  
Early Stage ◽  
Characteristic Curve ◽  
Diagnostic Value ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cutoff Value ◽  
Protein Assay ◽  
N Protein ◽  
Positive Rate

AbstractObjectiveThis study aimed to explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid(N) protein assay in the early stage of SARS-COV-2 infection.MethodSerum N protein in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay is used to detect serum N protein antibodies in the above population.Results50 cases of SARS-CoV-2 nucleic acid positive and SARS-CoV-2 antibody negative patients had a serum N protein positive rate of 76%, including 2% with a concentration of 10.00-49.99 pg / mL, 8% with a concentration of 50.00-99.99 pg / mL, 22% with a concentration of 100.00 - 299.99 pg/mL, and 44% with a concentration≥ 300.00 pg / mL. 37 samples of patients with serum SARS-CoV-2 antibody positive after infection had a serum SARS-CoV-2 N protein positive rate of 2.7%, of which 2.7% had the concentration of 10.00-49.99 pg / mL and 0% had the concentration of 50.00-99.99 pg / mL, 100.00 −299.99 pg / mL, and >300.00 pg / mL. Serum N protein test results of 633 non-SARS-COV-2 infected patients including pregnant women, other respiratory infections, and increased rheumatoid factor were all negative, having a serum N protein concentration less than 10.00 pg/mL, with a specificity of 100%. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was 0.9756 (95% confidence interval 0.9485-1.000, p <0.0001), sensitivity and specificity were 92% (95% confidence interval 81.16% to 96.85%) and 96.84% (95% confidence interval 95.17% to 97.15%). The best CUTOFF value is 1.850 pg / mL.ConclusionThe measurement of SARS-COV-2 serum N protein has a high diagnostic value for the infected patients before the antibody appears, and shortens the window period of serological diagnosis. The laboratory needs to establish an individual CUTOFF value according to purpose of the application.

scholarly journals Progastrin, a New Blood Biomarker for Multiple Cancers Allowing a New Strategy for Screening, Early Detection and Monitoring

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 211s-211s
Author(s):  
A. Prieur ◽  
V. Kepenekian ◽  
T. Mazard ◽  
L. Payen ◽  
D. Maucourt-Boulch ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Screening ◽  
Peritoneal Carcinomatosis ◽  
Cancer Patients ◽  
Early Stage ◽  
Diagnostic Value ◽  
Stage Ii ◽  
Breast Cancers ◽  
Different Types

Background: The majority of cancers evolve for years before becoming symptomatic. But once symptomatic, it is often too late for the patients to be cured. It is thus of paramount importance to improve early cancer screening in the general population as well as in genetically predisposed individuals. Moreover, although there is an undeniable progress in treatments, in particular in the immuno-oncology field, there is a growing need for circulating biomarkers to monitor treatment efficacy to better impact patient health and social economics. Aim: Progastrin (PG) is abnormally released in the blood of patients with colorectal cancer (CRC), as the gene coding for PG is a direct target of the WNT/β-catenin oncogenic pathway involved in tumorigenesis of many organs and activated from the very first steps of tumorigenesis, allowing the detection of PG in early stage cancers. The objective was to assess the diagnostic value of PG in a series of different types of cancers (early and advanced stages), as well as the role of PG as a circulating biomarker for treatment follow-up in patients with peritoneal carcinomatosis, a metastatic disease where imaging monitoring is impossible (due to the small size of lesions). Methods: Progastrin was measured in plasma EDTA samples using the ELISA cancerREAD technology. For the evaluation of PG in cancer patients, 673 samples were collected for comparison with 119 healthy volunteers. For the follow-up monitoring, patients were enrolled during management of peritoneal carcinomatosis (before or after neoadjuvant chemotherapy, or surgery). The diagnostic value of PG concentrations at inclusion in 190 GI cancer patients was assessed against 80 control samples. Results: Progastrin was detected in 77% of cancer patients, all cancers combined. The diagnosis area under the ROC curve of PG was 0.9114, P < 0.0001. Sensitivity ranged from 71% (breast cancer) to 87% (skin melanoma). All the 15 different types of cancers tested were positive. Early stage detection was assessed for colorectal and breast cancers with a sensitivity of 62.5% for adenomatous polyps, and 68.2% for stage 0 and I breast cancers. Sensitivity increased up to 82% for stage II colorectal cancer and to 78% for stage II-IV breast cancers. For the follow-up of peritoneal carcinomatosis patients, median PG levels decreased whatever the GI subtype with sequential treatments from 4.4 pM at inclusion time, to 1.3 after adjuvant chemotherapy. A trend for better PFS was observed in patients with PG decline after surgery. Conclusion: Progastrin assay is a simple and inexpensive blood test exhibiting high diagnostic accuracy for multiple gastro-intestinal, gynecologic, skin cancers. It may be used for cancer screening before tumor localization. It also exhibits promising therapeutic monitoring value during treatment in advanced CRC patients. Assessment of PG value as a multitumor screening biomarker, and as a monitoring test, is ongoing.

scholarly journals Evaluation of the auxiliary diagnosis value of antibodies assays for the detection of novel coronavirus (SARS-Cov-2)

2020 ◽  
Author(s):  
Gao Yong ◽  
Yuan Yi ◽  
Li Tuantuan ◽  
Wang Xiaowu ◽  
Li Xiuyong ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Early Stage ◽  
Clinical Information ◽  
Diagnostic Value ◽  
Nucleic Acid Detection ◽  
Course Of Illness ◽  
Combined Use ◽  
Hospitalization Period ◽  
Positive Rate ◽  
Novel Coronavirus

AbstractBackgroundThe spread of an novel coronavirus (SARS-CoV-2, previously named 2019-nCoV) has already taken on pandemic proportions, affecting over 100 countries in a matter of weeks. Elucidating the diagnostic value of different methods, especially the auxiliary diagnosis value of antibodies assays for SARS-CoV-2 infection is helpful for improving the sensitivities of pathogenic-diagnosis, providing timely treatment, and differentiating the infected cases from the healthy, thus preventing further epidemics.MethodsMedical records from 38 patients with confirmed SARS-CoV-2 infection in the Second People’s Hospital of Fuyang from January 22, 2020 to February 28, 2020 were collected and retrospectively analyzed. Specimens including throat swabs, sputum and serum were collected during the hospitalization period, viral RNAs and serum IgM-IgG antibodies to SARS-CoV-2 were measured respectively. The detectability of different methods as well as the auxiliary diagnosis value of antibodies test for SARS-CoV-2 infection were analyzed.ResultsAmong 38 patients, the total seropositive rate for IgM and IgG was 50.0% and 92.1%, respectively. Two patients remained seronegative throughout the course of illness. In the early phase of illness, the RNA test for sputum specimens possessed the highest detectability(92.3%), followed by the the RNA test for throat swabs (69.2%), and the antibodies assays presented lower positive rates(IgM, 23.0%, IgG, 53.8%). While, the sensitivity of antibodies assays overtook that of RNA test since day 8 after onset (IgM, 50.0%; IgG, 87.5%). Of note, the positive rate of throat swabs was only 13.0% for cases in later phase(≥15 d.a.o), and the sensitivities of IgM and IgG rose to 52.2% and 91.3%, respectively. Combined use of antibodies assay and qRT-PCR at the same time was able to improve the sensitivities of pathogenic-diagnosis, especially for the throat swabs group at the later stage of illness. Moreover, most of these cases with undetectable viral RNA in throat swabs specimens at the early stage of illness were able to be IgM/IgG seropositive after 7 days.ConclusionsThe antibodies detection against SARS-CoV-2 offers vital clinical information for physicians, and could be used as an effective supplementary indicator for suspected cases of negative viral nucleic acid detection or in conjunction with nucleic acid detection in the diagnosis of suspected cases.

scholarly journals Metagenomic Next-Generation Sequencing In Febrile Neutropaenia of Children Hematological And Malignant Diseases

2021 ◽  
Author(s):  
Linglong Hu ◽  
Juxiang Wang ◽  
Zhen Huang ◽  
Zhou Yang ◽  
Tingting Huang ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Malignant Tumor ◽  
Pathogen Detection ◽  
Treatment Strategies ◽  
Diagnostic Value ◽  
Clinical Treatment ◽  
Next Generation ◽  
High Positive Rate ◽  
Positive Rate ◽  
Generation Sequencing

Abstract Objective: To evaluate the diagnostic value of metagenomic next-generation sequencing in febrile neutropaenia of Hematological and malignant tumor children. Methods: We retrospectively studied the diagnostic value of metagenomic next-generation sequencing in febrile neutropaenia of Hematological and malignant tumor children in the Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University from July 2018 to December 2019. Children with neutropenia and fever for more than 72 hours were sent for mNGS analysis together with traditional pathogen detection tests. The positive rate of pathogen detection and the following change of clinical treatment strategy was analyzed. Furthermore the duration of fever was compared between patients receiving both mNGS and traditional tests and those only had pathogen detected by traditionally methods. Results: The positive rate of mNGS was 75.6% (28/37cases), and that of the two methods combined was 86.4% (32/37cases). In these patients with long duration of fever, the detection positivity for bacteria, fungi, and viruse detection was high, and mycoplasma and rickettsias were also found. Among all the cases reported, clinical treatment strategies were changed in 9 cases due to the pathogen detection. The duration of fever of patients receiving mNGS together with traditional tests was shorter than those only had traditional ones (7.84d±0.17 vs. 8.39d±0.25, respectively, P<0.001) .Conclusion: Due to high positive rate of mNGS in pathogen detection, active treatment can be taken in time, infections can be controlled earlier. It has a positive effect on the outcome of febrile neutropaenia patients.

scholarly journals Discovery and Validation of Serum MicroRNAs as Early Diagnostic Biomarkers for Prostate Cancer in Chinese Population

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Ji Lyu ◽  
Lin Zhao ◽  
Fubo Wang ◽  
Jin Ji ◽  
Zhi Cao ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Chinese Population ◽  
Prostate Volume ◽  
Early Stage ◽  
Diagnostic Value ◽  
Serum Markers ◽  
Diagnostic Tools ◽  
Serum Samples ◽  
Positive Rate ◽  
Serum Micrornas

Prostate cancer (PCa) incidence has been rising in Chinese population. Current PSA-based biopsy has limited positive rate. Our research focused on development of serum markers for the diagnosis of PCa in patients with elevated PSA. miRNAs are found to be aberrantly expressed in many types of cancer. They are readily detectable in plasma and serum. Currently, miRNAs are being evaluated as potential prognostic and diagnostic tools for many types of cancer. We first profiled global serum miRNAs in a pilot set of PCa and benign prostatic hyperplasia (BPH) cases undergoing TRUS-guided prostate biopsy due to elevated PSA levels. A total of 20 differentially expressed miRNAs were discovered by high throughput microarray for further testing using qRT-PCR. In the training phase with 78 PCa and 77 BPH cases, miR-365a-3p, miR-4286, miR-424-5p, miR-27a-3p, and miR-29b-3p were found to have potential diagnostic value. The Logistics regression equation was established by 5 parameters including PSA, prostate volume, miR-4286, miR-27a-3p, and miR-29b-3p and ROC analysis of this model was made with AUC up to 0.892 (95% CI: 0.832-0.937, sensitivity 78.95%, and specificity 92.21%). The panel had excellent diagnostic performance and its significance was confirmed in 100 serum samples in the validation cohort. Overall, we found a panel of serum microRNAs that have considerable clinical significance in detecting early-stage prostate cancer. When combined with PSA and prostate volume, these microRNAs exhibit favorable diagnostic potency.

CLINICAL SIGNIFICANCE OF SERUM CAVEOLIN-1 LEVELS IN GASTRIC CANCER PATIENTS

2018 ◽  
Vol 40 (4) ◽  
pp. 323-327 ◽  
Author(s):  
F Tas ◽  
S Karabulut ◽  
K Erturk ◽  
D Duranyildiz
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Histological Grade ◽  
Clinical Importance ◽  
Disease Stage ◽  
Control Group ◽  
Tissue Samples ◽  
Caveolin 1 ◽  
Study Results ◽  
Gastric Cancer Patients

Aim: Caveolin-1 plays a significant role in the pathogenesis of various carcinomas and its expression affects the survival of cancer patients. However, the molecular function of caveolin-1 and its possible clinical importance has remained uncertain in gastric cancer. No clinical trial has examined serum caveolin-1 levels in gastric cancer patients so far, instead all available results were provided from studies conducted on tissue samples. In the current study, we analyzed the soluble serum caveolin-1 levels in gastric cancer patients, and specified its associations with the clinical factors and prognosis. Material and Methods: Sixty-three patients with pathologically confirmed gastric cancer were enrolled into the trial. Serum caveolin-1 concentrations were detected by ELISA method. Thirty healthy subjects were also included in the study. Results: The median age of patients was 62 years, ranging from 28 to 82 years. The serum caveolin-1 levels in gastric cancer patients were significantly higher than those in control group (p < 0.001). The common clinical parameters including patient age, sex, lesion localization, histopathology, histological grade, disease stage, and various serum tumor markers (e.g. LDH, CEA, and CA 19.9) were not found to be associated with serum caveolin-1 levels (p > 0.05). Similarly, no correlation existed between serum caveolin-1 concentration and chemotherapy responsiveness (p = 0.93). Furthermore, serum caveolin-1 level was not found to have a prognostic role (p = 0.16). Conclusion: Even though it is neither predictive nor prognostic, serum caveolin-1 level may be a valuable diagnostic indicator in patients with gastric cancer. Key

scholarly journals Novel genomic classifier for early stage colorectal cancer patients

2018 ◽  
Vol 29 ◽  
pp. viii33-viii34
Author(s):  
E. Letellier ◽  
M. Schmitz ◽  
A. Ginolhac ◽  
E. Koncina ◽  
M. Marchese ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document